Schedule 13G Filing by Bigger Capital and Related Entities for bioAffinity Technologies, Inc.

The Schedule 13G filing, dated October 1, 2025, discloses the beneficial ownership of Common Stock in bioAffinity Technologies, Inc. by Bigger Capital Fund, LP, Bigger Capital Fund GP, LLC, District 2 Capital Fund LP, District 2 Capital LP, District 2 GP LLC, District 2 Holdings LLC, and Michael Bigger. As of September 29, 2025, Bigger Capital and Bigger GP each beneficially owned 2.89% of the outstanding shares, while District 2 CF, District 2, District 2 GP, and District 2 Holdings each also owned 2.89%. Michael Bigger, as the managing member of Bigger GP and District 2 Holdings, beneficially owned approximately 5.79% of the outstanding shares. The filing also notes that the Reporting Persons sold all of their Common Stock by September 30, 2025, and thus no longer hold at least 5.00% of the Issuer's Common Stock. The filing is made pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934.